For most of the AML patients (5 out of 7 analyzed patients), only few WT1-specific CD8 + T-cells were discovered in their BM samples; therefore, we investigated the implications of patients’ HLA-A allele on WT1 peptide presentation. This evidence concerns the gene CD8A and acute myeloid leukemia.